JPMorgan Upgrades Passage Bio Inc. (PASG) to Overweight, Following Clinical Trial Update
Tweet Send to a Friend
JPMorgan analyst Anupam Rama upgraded Passage Bio Inc. (NASDAQ: PASG) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
